Sep 23, 2021
In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer on best practices and strategies for improving clinician and patient communication, medication adherence, and collaboration in the community when it comes to treating schizophrenia.
Optional CE Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CE credit, click https://nei.global/POD21-Schiz
Learning Objectives: After completing this educational activity, you should be better able to:
- Demonstrate strategies that involve patient and caregivers in shared informed decision-making for treatment goals
- Discuss the role of social aspects of community and behavioral health settings on patient experiences and treatment outcomes
- Address best practices for the use of telemedicine when monitoring treatment for schizophrenia and the use of LAIs
Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MDs and DOs: NEI designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CE credit.
Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as providers of “formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 1.25 continuing education hours of pharmacotherapeutics.
Peer Review: The content was peer-reviewed by an MD specializing in forensic psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CE activity.
Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.
Interviewer
Andrew J. Cutler, MD
Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY
Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA
Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva
Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris
Interviewee
Jonathan M. Meyer, MD
Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA
Consultant/Advisor: Acadia, Alkermes, Intra-Cellular, Neurocrine
Speakers Bureau: Acadia, Alkermes, Intra-Cellular, Neurocrine, Noven, Otsuka, Sunovion, Teva
Pre-Interview Author
Sabrina K. Bradbury-Segal, PhD
Medical Writer, Neuroscience Education Institute, Carlsbad, CA
No financial relationships to disclose.
The Planning Committee and Peer Reviewer have no financial relationships to disclose.
Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.
Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture
Support: This activity is supported by an unrestricted educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.
Released: September 23, 2021 CE credit expires: September 23, 2024